General Principles Of Management

Precautionary measures must be tailored to the severity of the specific immunologic defect.
Severe immunodeficiencies, such as Severe Combined Immunodeficiency (SCID), require strict patient isolation.
Universal precautions are mandatory.
Thorough hand hygiene must be frequently practiced by patients and close contacts.
The use of masks is highly recommended to avoid transmissible infections.

Live viral or bacterial vaccines are strictly contraindicated in patients with complete cellular immune defects.
Prohibited vaccines include oral polio, MMR, varicella, and BCG.
Patients receiving Immunoglobulin Replacement Therapy (IgRT) do not require routine vaccinations.
IgRT provides passive immunization against common pathogens.
Administration of IgRT can interfere with vaccination efficacy.
Live vaccines should be delayed for an 8-month waiting period after the last intravenous immunoglobulin infusion.

Pharmacologic Prophylaxis

Disease / Defect	Targeted Pathogens	Recommended Prophylaxis
SCID	Pneumocystis jiroveci, Fungi, Viruses	TMP-SMX, Fluconazole, Acyclovir.
Chronic Granulomatous Disease (CGD)	Staphylococcus aureus, Aspergillus	TMP-SMX, Itraconazole.
Leukocyte Adhesion Deficiency (LAD)	S. aureus, Gram-negative bacilli	Targeted antibiotic prophylaxis.
Hyper-IgE Syndrome (Job)	S. aureus, Streptococcus pneumoniae, Candida	TMP-SMX, Itraconazole.
Terminal Complement Defects	Neisseria meningitidis	Prophylactic penicillin.

IgRT is the primary therapy for defects characterized by absent antibody production.
This includes X-Linked Agammaglobulinemia (XLA) and Common Variable Immunodeficiency (CVID).
The goal is to maintain IgG trough levels above 800 mg/dL.
Adequate trough levels prevent serious bacterial illnesses and enteroviral meningoencephalitis.

Administration Route	Typical Dosing Regimen	Key Clinical Features
Intravenous (IVIG)	400 to 600 mg/kg every 3 to 4 weeks.	May cause rate-related adverse reactions. Requires premedication in some patients.
Subcutaneous (SCIG)	100 to 200 mg/kg per week.	Provides more flexibility for home administration. Highly tolerated in patients with IgA deficiency.

Allogeneic HSCT is the definitive and potentially curative treatment for numerous PIDs.
Curable conditions include SCID, CGD, LAD, and Wiskott-Aldrich syndrome.
For infants with SCID, optimal survival (approaching 95%) is achieved when HSCT is performed within the first 100 days of life.
An HLA-identical sibling is the preferred donor to maximize survival probability.
T-cell depletion of the graft is routinely employed in mismatched transplants to prevent Graft-Versus-Host Disease (GVHD).

Ex vivo gene transfer utilizes lentiviral vectors to provide long-term immune reconstitution.
Gene therapy is clinically successful for X-linked SCID, ADA-SCID, and Wiskott-Aldrich syndrome.
Lentiviral vectors significantly reduce the risk of secondary leukoproliferative complications seen with older vectors.
Enzyme replacement therapy with PEG-ADA serves as a temporary bridge to definitive treatment for ADA-SCID patients.

Immunologic Disorder	Clinical Phenotype	Targeted Therapy
IPEX Syndrome	Severe autoimmune enteropathy, endocrinopathy	Cyclosporine, Tacrolimus, Sirolimus.
Autoimmune Lymphoproliferative Syndrome (ALPS)	Massive lymphadenopathy, cytopenias	Mycophenolate mofetil, Sirolimus.
Hemophagocytic Lymphohistiocytosis (HLH)	Cytokine storm, macrophage activation	Corticosteroids, Etoposide (as a bridge to HSCT).
Chronic Granulomatous Disease (CGD)	Granulomas, absent respiratory burst	Subcutaneous Interferon-gamma (reduces severe infections).
Hereditary Angioedema (C1-INH Deficiency)	Episodic deep nonpitting edema	Plasma-derived C1-INH concentrate, Lanadelumab.